Amerika Serikat - Inggris - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - azithromycin tablets, are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see dosage and administration (2)] .   [see use in specific populations (8.4) and clinical studies (14.2)] azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:‑ to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying a

Amerika Serikat - Inggris - NLM (National Library of Medicine)

cardinal health - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - azithromycin tablets, usp are indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae . acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis or streptococcus pneumoniae . community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness

Amerika Serikat - Inggris - NLM (National Library of Medicine)

proficient rx lp - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - azithromycin tablets, usp are indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae . acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis or streptococcus pneumoniae . community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness

Israel - Inggris - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - capsules - azithromycin as dihydrate 250 mg - azithromycin - azithromycin - infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

Israel - Inggris - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - powder for suspension - azithromycin as dihydrate 200 mg / 5 ml - azithromycin - azithromycin - infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

major pharmaceuticals - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. azithromycin tablets, are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see dosage and administration (2)] .   [see use in specific populations (8.4) and clinical studies (14.2)] azithromycin should not be used in patients wi

Amerika Serikat - Inggris - NLM (National Library of Medicine)

cambridge therapeutics technologies, llc - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. azithromycin tablets, are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see dosage and administration (2)] . - acute bacterial exacerbations of chronic bronchitis due to haemophilus influenzae , moraxella catarrhalis , or str

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

apotex nz ltd - azithromycin dihydrate 261.02mg equivalent to 250 mg azithromycin - film coated tablet - 250 mg - active: azithromycin dihydrate 261.02mg equivalent to 250 mg azithromycin excipient: calcium hydrogen phosphate dihydrate croscarmellose sodium hyprolose magnesium stearate opadry white 31k58875 purified water - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections (acute bacterial bronchitis, community acquired pneumonia). 2. upper respiratory tract infections (acute sinusitis, acute streptococcal pharyngitis, acute otitis media). 3. uncomplicated skin and skin structure infections (uncomplicated infections, sexually transmitted diseases, pelvic inflammatory disease). 4. chlamydia trachomatis conjunctivitis and trachoma. 5. prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease. azithromycin is indicated for use in children for the treatment of the following infections: 1. lower respiratory tract infections (acute bacterial bronchitis, community acquired pneumonia). 2. upper respiratory tract infections (acute sinusitis, acute streptococcal pharyngitis, acute otitis media). 3. uncomplicated skin and skin structure infections (uncomplicated infections, sexually transmitted diseases, pelvic inflammatory disease). 4. prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease. 5. acute streptococcal pharyngitis/tonsillitis. 6. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20 mg/kg azithromycin dose appears to be as effective as penicillin in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 7. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

apotex nz ltd - azithromycin dihydrate 522.04mg equivalent to 500 mg azithromycin - film coated tablet - 500 mg - active: azithromycin dihydrate 522.04mg equivalent to 500 mg azithromycin excipient: calcium hydrogen phosphate dihydrate croscarmellose sodium hyprolose magnesium stearate opadry white 31k58875 purified water - azithromycin is indicated for use in adults for the treatment of the following infections of mild to moderate severity: 1. lower respiratory tract infections (acute bacterial bronchitis, community acquired pneumonia). 2. upper respiratory tract infections (acute sinusitis, acute streptococcal pharyngitis, acute otitis media). 3. uncomplicated skin and skin structure infections (uncomplicated infections, sexually transmitted diseases, pelvic inflammatory disease). 4. chlamydia trachomatis conjunctivitis and trachoma. 5. prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease. azithromycin is indicated for use in children for the treatment of the following infections: 1. lower respiratory tract infections (acute bacterial bronchitis, community acquired pneumonia). 2. upper respiratory tract infections (acute sinusitis, acute streptococcal pharyngitis, acute otitis media). 3. uncomplicated skin and skin structure infections (uncomplicated infections, sexually transmitted diseases, pelvic inflammatory disease). 4. prevention of infection due to mycobacterium avium-intracellulare complex (mac) disease. 5. acute streptococcal pharyngitis/tonsillitis. 6. note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. the 20 mg/kg azithromycin dose appears to be as effective as penicillin in the treatment of streptococcal pharyngitis. however, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present. 7. chlamydia trachomatis conjunctivitis and trachoma in children 12 months or older.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - azithromycin dihydrate, quantity: 524.1 mg (equivalent: azithromycin, qty 500 mg) - solution, powder for - excipient ingredients: sodium hydroxide; citric acid monohydrate - community acquired pneumonia caused by susceptible organisms in patients who require initial intravenous therapy. in clinical studies efficacy has been demonstrated against chlamydia pneumoniae, haemophilus influenzae, legionella pneumophilia, moraxella catarrhalis, mycoplasma pneumoniae,staphylococcus aureus and streptococcus pneumoniae